Since dysregulation of the PERK/eIF2α pathway is a potential pathophysiologic factor contributing to AD, PERK has emerged as a novel potential therapeutic target for AD treatment (Ma and Klann, 2014; Rozpedek et al., 2015; Ohno, 2018). Here, EIF2AK3 is linked to Alzheimer disease.